Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus
- PMID: 15210897
- DOI: 10.1212/01.wnl.0000130499.91775.2c
Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus
Abstract
The authors prospectively followed 14 patients treated with thalidomide for cutaneous lupus erythematosus (CLE), in order to evaluate the occurrence of peripheral neuropathy (PN) and to assess whether PN correlates with thalidomide dose. The patients were followed for up to 24 months with neurologic and electrophysiologic evaluations. Seven patients (50%) developed sensory axonal PN. The median time free from PN was 14 months. PN occurred after 10 months in the majority of patients. No correlations were found between thalidomide cumulative dose and occurrence of PN (Mann-Whitney U test; p > 0.16).
Comment in
-
Thalidomide neuropathy: too much or too long?Neurology. 2004 Jun 22;62(12):2158-9. doi: 10.1212/01.wnl.0000131766.90137.df. Neurology. 2004. PMID: 15210874 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical